Spero Therapeutics (SPRO) Set to Announce Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) will be issuing its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 25.67% and a net margin of 14.74%. During the same quarter in the previous year, the company posted ($0.23) earnings per share. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Trading Down 3.1 %

Shares of Spero Therapeutics stock opened at $1.27 on Friday. Spero Therapeutics has a 1 year low of $1.01 and a 1 year high of $1.89. The company has a market cap of $68.57 million, a P/E ratio of 3.97 and a beta of 0.63. The stock has a 50-day moving average price of $1.30 and a 200 day moving average price of $1.37.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright reduced their price target on shares of Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday. TD Cowen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, August 6th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.